PWE-235 Long term subcutaneous saline and magnesium administration in patients with a short bowel. 10 year outcomes

Small, M.; Brundrett, Diane; Nightingale, Julie

doi:10.1136/gutjnl-2015-309861.681

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Appendix 1; for all online suppl. material, see www.karger.com/doi/10.1159/000501121) to identify original research describing subcutaneous administration of magnesium (sulfate) in adults or children yielded 14 publications meeting our inclusion criteria [10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23] (Fig. 2; Table 1, Table 2, Table 3, Table 4).…”

Section: Discussionmentioning

confidence: 99%

“…2; Table 1, Table 2, Table 3, Table 4). A total of 5 case reports [10, 11, 12, 13, 17] and 3 publications reporting 2 retrospective case series [14, 15, 16] described experiences of patients with gastrointestinal conditions using subcutaneous magnesium supplementation. Seven case reports were identified in nongastrointestinal conditions [18, 19, 20, 21, 22, 23, 24] but one was excluded as there was no English language abstract and the full text was only available in German [24].…”

Section: Discussionmentioning

confidence: 99%

“…The frequency of infusion ranged between 2 and 7 days per week. In the 2 publications that reported typical weekly doses, the ranges were 8–28 mmol magnesium sulfate/week [11] and a mean of 21 ± 9.8 (range 8–40) mmol per week [14]. Two reports addressed duration of therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Two reports addressed duration of therapy. McDermott et al [10] reported a total of 24 months of therapy, while Small et al [14] noted average treatment durations of 17.4 ± 34 and 10 ± 8.5 months for those receiving 4 and 8 mmol of magnesium per infusion, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Subcutaneous Magnesium Sulfate to Correct High-Output Ileostomy-Induced Hypomagnesemia

Makowsky

Bell

Gramlich

2019

Case Rep Gastroenterol

View full text Add to dashboard Cite

Fluid and magnesium abnormalities are common in patients with high-output stomas. Subcutaneous magnesium administration may be more feasible for long-term management in ambulatory patients, but magnesium sulfate is approved only for intravenous or intramuscular injection. We describe the management of chronic hypomagnesemia and dehydration secondary to a high-output ileostomy following radiation and chemotherapy for anal squamous cell carcinoma with intermittent home-based subcutaneous magnesium infusions in a 61-year-old female with a history of Crohn’s disease and multiple bowel resections. Despite aggressive management with intravenous magnesium sulfate and oral magnesium glucoheptonate over 8 months, 49% of her magnesium concentrations were <0.60 mmol/L (mean 0.61 ± 0.09) necessitating 4 emergency, 1 hospital, and 4 infusion clinic visits. After initiation of subcutaneous magnesium sulfate, all magnesium concentrations were >0.60 mmol/L (mean 0.79 ± 0.08 mmol/L over 9 months). The patient tolerated the infusions well, only developing one minor episode of infusion-related cellulitis. A systematic review of the literature identified 14 reports where subcutaneous magnesium sulfatewas effective and treatment for adults or children with hypomagnesemia was safe. Home-based intermittent administration of subcutaneous magnesium may be a helpful and safe intervention to temporarily prevent and treat select patients with recurrent symptomatic hypomagnesemia.

show abstract